C677T and A1298C MTHFR polymorphisms in the etiology of neural tube defects in Spanish population;Implicación de los polimorfismos C677T y A1298C del gen MTHFR en el desarrollo de los defectos del tubo neural en la población española

Medicina Clinica

Volumn 120, Issue 12, 2003, Pages 441-445

  Gutiérrez Revilla, José I Ignacio ^a   Pérez Hernández, Flora ^b   Calvo Martín, M Teresa ^a   Tamparillas Salvador, Manuel ^a   Gracia Romero, Jesús ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b Farmaceutica de Atencion Primaria   (Spain)

Author keywords

A1298C; C677T; Metilentetrahidrofolate reductase; Neural tube defects

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DNA FRAGMENT;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; MALE; MOTHER; NEURAL TUBE DEFECT; POLYMERASE CHAIN REACTION; PREVALENCE; RESTRICTION MAPPING; SIBLING; SPAIN;

EID: 0038294361     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13045517     Document Type: Article

References (30)

1. Goyette P, Summer JS, Milos R, Duncan AMV, Rosenblatt DS, Mattews RG, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 1994;7:195-200.
2. Van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbeis FJM, Eskes TKAB, Van den Heuvet LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;21:1070-1.
3. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
4. Whitehead AS, GallagHer P, Mills JL, Kirke PN, Burke H, Molloy AM, et al. A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. Q J Med 1995;88:763-6.
5. Van der Put NM, Van den Heuvel LP, Steegers-Theunissen RP. Decreased methylene tetrahydrofolate reductase activity due to the 677C-T mutation in families with spina bifida offspring. J Mol Med 1996;74:691-4.
6. De Franchis R, Buoninconti A, Mandato C, Pepe A, Sperandeo MP, Del Gado R, et al. The C677T mutation of the 5,10-methylenetetrahydrofolate reductase gene is a moderate risk factor for spina bifida in Italy. J Med Genet 1998;35:1009-13.
7. Papapetrou C, Lynch SA, Burn S, Edwards WH. Methylenetetrahydrofolate reductase and neural tube defects. Lancet 1996; 6: 58.
8. Kirke PN, Mills JL, Whitehead AS, Molloy A, Scott JM. Methylenetetrahydrofolate reductase mutation and neural tube defects. Lancet 1996; 348: 1037-8.
9. Engberseb AMT, Franken DG, Boers GHJ, Stevens EMB, Tribels FJM, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-50.
10. Kluijtmans LAJ, Van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, Van Oost BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
11. Harmon DL, Woodside JV, Yarnell JWG, McMaster D, Young IS, McCrum EE, et al. The common «thermolabile» variant of methylene tetrahydrofolate reductase is a mayor determinant of mild hyperhomocysteinemia. Q J Med 1996;89:571-7.
12. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, et al. Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349:1591-3.
13. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993;86:703-8.
14. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:149-51.
15. Ou CY, Stevenson RE, Brown VK, Schwartz CE, Allen WP, Khoury MJ, et al. 5,10 methilenetetrahydrofolate reductase genetic polymorphism as a risk factor for neural tube defects. Am J Med Genet 1996;63:610-4.
16. González Ordóñez AJ, Medina Rodríguez JM, Fernández Álvarez CR, Sánchez García J, Fernández Carreira JM, Álvarez Martínez MV, et al. Reducción de niveles altos de homocisteína total con ácido fólico y vitamina B en pacientes con tromboembolismo venoso: relación entre la respuesta y el genotipo C677T de la enzima metilentetrahidrofolato reductasa (MTHFR). Med Clin (Barc) 2000;114:7-12.
17. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of miocardial infarction in US physicians. Circulation 1996;94: 2410-6.
18. Chen J, Giovannucci E, Kelsey K. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56:4862-4.
19. Ma J, Stampfer MJ, Giovannucci E. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997;57:1098-102.
20. Muñoz-Morán E, Diéguez-Lucena JL, Fernández-Arcas N, Perán-Mesa S, Reyes-Engel A. Genetic selection and folate intake during pregnancy. Lancet 1998;352:1120-1.
21. Steegers-Theunissen RPM, Boers GHJ, Tijbels FJM, Finkelstein JD, Blom HJ, Thomas CMG, et al. Maternal hyperhomocysteinemia: a risk factor for neural tube defects? Metabolism 1994;43: 1475-80.
22. Van der Put NMJ, Gabreëls F, Stevens EMB, Smeitink JAM, Trijbels FJM, Eskes TKAB, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube defects? Am J Hum Genet 1998;62:1044-51.
23. Barber R, Sahlat S, Hendricks K, Joggerst B, Larsen R, Suárez L, et al. Investigation of folate pathway gene polymorphisms and the incidence of neural tube defects in a Texas hispanic population. Mol Genet Metab 2000;70:45-52.
24. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
25. Nieto C. Suplementación con ácido fólico en la prevención de defectos del tubo neural. Med Clin (Barc) 2002;118:357.
26. Mornet E, Muller F, Lenvoise-Furet A, Delezoide AL, Col JY, Simon-Bouy B, et al. Screening of the C677T mutation on the methylenetetrahydrofolate reductase gene in French patients with neural tube defects. Hum Genet 1997;100: 512-4.
27. Boduroglu K, Alikasiflogu M, Anar B, Tuncbilek E. 677CT mutation on the methylenetetrahydrofolate reductase gene is not a risk factor for neural tube defects in Turkey. Arch Dis Child Fetal Neonatal 1998;78:235.
28. Koch MC, Stegmann K, Ziegler A, Schröter B, Ermert A. Evaluation of the MTHFR C677T allele and the MTHFR gene locus in a German spina bifida population. Eur J Pediatr 1998;157: 487-92.
29. Jonson WG, Stenroos ES, Heath SC, Chen Y, Carroll R, McKoy VV, et al. Distribution of alleles of the methylenetetrahydrololate reductase (MTHFR) C677T gene polymorphism in familial spina bifida. Am J Med Genet 1999;87:407-12.
30. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93:7-9.